Nail psoriasis is a common and disabling manifestation of cutaneous plaque-type psoriasis. Treatment of nail psoriasis is often unsuccessful and frequently requires prolonged and tedious treatment regimens to achieve or maintain remission. The clinician may choose from a variety of treatment modalities, including topical, intralesional, radiation, and systemic modes of therapy. The objective of this review is to summarize the available treatment options and assess their effectiveness for the treatment of nail psoriasis.
de BerkerD.A.R., BaranR., DawberR.P.R.The nail in dermatological diseases. In: BaranR., DawberR.P.R., de BerkerD.A.R., HanekeE., TostiA., editors. Baran and Dawber's diseases of the nails and their management, 3rd ed. Malden, Mass.: Blackwell Science; 2001: 172–222.
SammanP.D., FentonD.A.Psoriasis. In: SammanP.D., FentonD.A., editors. Samman's the nails in disease. 5th ed. Oxford, Boston: Butterworth-Heinemann; 1994: 56–71.
4.
WilliamsonL., DalbethN., DockertyJ.L., GeeB.C., WeatherallR., WordsworthB.P.Extended report: nail disease in psoriatic arthritis—clinically important, potentially treatable and often overlooked. Rheumatology (Oxford).2004; 43(6): 790–4.
5.
TanA.L., BenjaminM., ToumiH.The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis—a high-resolution MRI and histological study. Rheumatology (Oxford).2007; 46(2): 253–6.
6.
McGonagleD.Enthesitis: an auto inflammatory lesion linking nail and joint involvement in psoriatic disease. J Eur Acad Dermatol Venereol.2009; 23(suppl 1): 9–13.
7.
de JongE.M., SeegersB.A., GulinckM.K., BoezemanJ.B., van de KerkhofP.C.Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology.1996; 193(4): 300–3.
8.
JiaravuthisanM.M., SassevilleD., VenderR.B., MurphyF., MuhnC.Y.Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol.2007; 57(1): 1–27.
9.
RichP., ScherR.K.Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol.2003; 49(2): 206–12.
10.
ReichK.Approach to managing patients with nail psoriasis. J Eur Acad Dermatol Venereol.2009; 23(suppl 1): 15–21.
11.
BaranR., TostiA.Topical treatment of nail psoriasis with a new corticoid-containing nail lacquer formulation. J Dermatolog Treat.1999; 10(3): 201.
12.
Sanchez ReganaM., Martin EzquerraG., Umbert MilletP., Llambi MateosF.Treatment of nail psoriasis with 8% clobetasol nail lacquer: positive experience in 10 patients. J Eur Acad Dermatol Venereol.2005; 19(5): 573–7.
13.
RequenaL., ZamoraE., MartinL.Acroatrophy secondary to long-standing applications of topical steroids. Arch Dermatol.1990; 126(8): 1013–4.
TostiA., PiracciniB.M., CameliN.Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol.1998; 139(4): 655–9.
17.
RigopoulosD., GregoriouS., DanielC.R.IIITreatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology.2009; 218(4): 338–41.
18.
RigopoulosD., IoannidesD., PrastitisN., KatsambasA.Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Derm Venereol.2002; 82(2): 140.
19.
TzungT.Y., ChenC.Y., YangC.Y., LoP.Y., ChenY.H.Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. Acta Derm Venereol.2008; 88(3): 279–80.
20.
Sanchez ReganaM., Marquez BalbasG., Umbert MilletP.Nail psoriasis: a combined treatment with 8% clobetasol nail lacquer and tacalcitol ointment. J Eur Acad Dermatol Venereol.2008; 22(8): 963–9.
21.
ScherR.K., StillerM., ZhuY.I.Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis.2001; 68(5): 355–8.
22.
BianchiL., SodaR., DiluvioL., ChimentiS.Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open, prospective study. Br J Dermatol.2003; 149(1): 207–9.
23.
RigopoulosD., GregoriouS., KatsambasA.Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: a double-blind study. Acta Derm Venereol.2007; 87(2): 167–8.
24.
YamamotoT., KatayamaI., NishiokaK.Topical anthralin therapy for refractory nail psoriasis. J Dermatol.1998; 25(4): 231–3.
25.
FredrikssonT.Topically applied fluorouracil in the treatment of psoriatic nails. Arch Dermatol.1974; 110(5): 735–6.
26.
de JongE.M., MenkeH.E., van PraagM.C., van De KerkhofP.C.Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: a double-blind study. Dermatology.1999; 199(4): 313–8.
27.
CannavoS.P., GuarneriF., VaccaroM., BorgiaF., GuarneriB.Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study. Dermatology.2003; 206(2): 153–6.
28.
PeacheyR.D., PyeR.J., HarmanR.R.The treatment of psoriatic nail dystrophy with intradermal steroid injections. Br J Dermatol.1976; 95(1): 75–8.
29.
AbellE., SammanP.D.Intradermal triamcinolone treatment of nail dystrophies. Br J Dermatol.1973; 89(2): 191–7.
30.
de BerkerD.A., LawrenceC.M.A simplified protocol of steroid injection for psoriatic nail dystrophy. Br J Dermatol.1998; 138(1): 90–5.
31.
MarxJ.L., ScherR.K.Response of psoriatic nails to oral photochemotherapy. Arch Dermatol.1980; 116(9): 1023–4.
32.
Handfield-JonesS.E., BoyleJ., HarmanR.R.Local PUVA treatment for nail psoriasis. Br J Dermatol.1987; 116(2): 280–1.
33.
FinnertyE.F.Successful treatment of psoriasis of the nails. Cutis.1979; 23(1): 43–4.
34.
YuR.C., KingC.M.A double-blind study of superficial radiotherapy in psoriatic nail dystrophy. Acta Derm Venereol.1992; 72(2): 134–6.
35.
KwangT.Y., NeeT.S., SengK.T.A therapeutic study of nail psoriasis using electron beams. Acta Derm Venereol.1995; 75(1): 90.
36.
LindelofB.Psoriasis of the nails treated with grenz rays: a double-blind bilateral trial. Acta Derm Venereol.1989; 69(1): 80–2.
ArnoldW.P., GerritsenM.J., van de KerkhofP.C.Response of nail psoriasis to cyclosporin. Br J Dermatol.1993; 129(6): 750–1.
39.
FelicianiC., ZampettiA., ForleoP.Nail psoriasis: combined therapy with systemic cyclosporin and topical calcipotriol. J Cutan Med Surg.2004; 8(2): 122–5.
40.
MahrleG., SchulzeH.J., FarberL., WeidingerG., SteiglederG.K.Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol.1995; 32(1): 78–88.
41.
Lopez CastilloV., Molina GallardoI., Marti FajardoN., Martin HernandezJ.M., Jorda CuevasE.Severe nail psoriasis with a rapid response to acitretin. Clin Exp Dermatol.2009; 34(7): e332–3.
42.
TostiA., RicottiC., RomanelliP., CameliN., PiracciniB.M.Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol.2009; 145(3): 269–71.
KorverJ.E., LangewoutersA.M., Van De KerkhofP.C., PaschM.C.Therapeutic effects of a 12-week course of alefacept on nail psoriasis. J Eur Acad Dermatol Venereol.2006; 20(10): 1252–5.
45.
CassettyC.T., AlexisA.F., ShupackJ.L., StroberB.E.Alefacept in the treatment of psoriatic nail disease: a small case series. J Am Acad Dermatol.2005; 52(6): 1101–2.
46.
KorverJ.E., van de KerkhofP.C., PaschM.C.Alefacept treatment of psoriatic nail disease: how severe should nail psoriasis be?J Am Acad Dermatol.2006; 54(4): 742–3.
47.
LawryM.Biological therapy and nail psoriasis. Dermatol Ther.2007; 20(1): 60–7.
48.
BianchiL., BergaminA., de FeliceC., CapriottiE., ChimentiS.Remission and time of resolution of nail psoriasis during infliximab therapy. J Am Acad Dermatol.2005; 52(4): 736–7.
49.
RigopoulosD., GregoriouS., StratigosA.Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Br J Dermatol.2008; 159(2): 453–6.
50.
ReichK., NestleF.O., PappK.Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet.2005; 366(9494): 1367–74.
51.
RichP., GuptaA., WangA., JahreisA.Etanercept improves nail psoriasis. J Am Acad Dermatol.2005; 52(3, suppl 1): P184.
52.
RallisE., StavropoulouE., RigopoulosD., VerrosC.Rapid response of nail psoriasis to etanercept. J Rheumatol.2008; 35(3): 544–5.
53.
LugerT.A., BarkerJ., LambertJ.Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol.2009; 23(8): 896–904.
54.
IrlaN., YawalkarN.Marked improvement in nail psoriasis during treatment with adalimumab. Dermatology.2009; 219(4): 353–6.
55.
RigopoulosD., GregoriouS., LazaridouE.Treatment of nail psoriasis with adalimumab: an open label unblinded study. J Eur Acad Dermatol Venereol.2010; 24(5): 530–4.
56.
Van den BoschF., MangerB., GoupilleP.Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis.2010; 69(2): 394–9.
57.
KavanaughA., McInnesI., MeaseP.Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum.2009; 60(4): 976–86.
58.
RichP., LangleyR., GuzzoC., WangY., RosophL., GordonK.Improvement in nail psoriasis with ustekinumab, a new anti-IL-12/23P40 monoclonal antibody: results from a phase 3 trial. EADV2008, FP1007.
